Using information from a cell phone provider, searchers concentrated their efforts in waters to the west of Guam Monday as they continued looking for a 58-year-old man whose boat was reported ...

A patient with heavily pretreated relapsed/refractory diffuse large B-cell lymphoma achieved complete remission following ...

If you or a loved one has diffuse large B-cell lymphoma (DLBCL) that is no longer responding to treatment or came back after treatment, chimeric antigen receptor (CAR) T-cell therapy may be an option.

A recently developed cancer treatment called chimeric antigen receptor T-cell therapy (CAR T-cell therapy, for short) offers hope to people whose diffuse large B-cell lymphoma (DLBCL) has proved ...

Miklos Phase 1 Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults with Recurrent or Refractory B Cell Malignancies $11,034,982 University of California, San Francisco Mort Cowan Gene ...

Single-cell RNA sequencing (scRNA-seq) has confirmed that MM exhibits high intra-tumor heterogeneity, comprising a mixture of ...

Pull requests help you collaborate on code with other people. As pull requests are created, they’ll appear here in a searchable and filterable list. To get started, you should create a pull request.

This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody clustering, independent of ...

CD4 T helper cells are a type of white blood cell called a lymphocyte that serves an important role in your immune system. These cells help defend the body against infection by directing other "killer ...

Chimeric antigen receptor T (CAR-T) cell therapy targeting CD19 can significantly improve the long-term survival rate of patients with relapsed or refractory leukemia. However, CD19 absence or loss ...